Clinically accurate diagnosis of Alzheimer's disease via multiplexed sensing of core biomarkers in human plasma
Clinically accurate diagnosis of Alzheimer's disease via multiplexed sensing of core biomarkers in human plasma
复制标题
DOI：
10.1038/s41467-019-13901-z
复制
发表时间：
2020-01-08
影响因子：
16.6
通讯作者：
Park, Chan Beum
中科院分区：
文献类型：
--
作者：
Kim, Kayoung;Kim, Min-Ji;Park, Chan Beum
阿尔茨海默病（AD）是最普遍的神经退行性疾病，影响65岁以上的十分之一的人。尽管疾病严重，但由于神经心理学测试和神经影像学的准确性低或成本高，AD的早期诊断仍然具有挑战性。在这里，我们报告了使用密集排列的碳纳米管（CNT）对人血浆中多种AD核心生物标志物（t-tau，p-tau（181），A β（42）和A β（40））的临床准确和超灵敏检测。紧密包装和单向对齐的CNT传感器阵列具有高精度，灵敏度和准确性，证明了低变异系数（93.0%）。通过测量临床血液样品中t-tau/A β（42）、p-tau（181）/A β（42）和A β（42）/A β（40）的水平，传感器阵列成功地将临床诊断的AD患者与健康对照区分开，平均灵敏度为90.0%，选择性为90.0%，平均准确度为88.6%。
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, affecting one in ten people aged over 65 years. Despite the severity of the disease, early diagnosis of AD is still challenging due to the low accuracy or high cost of neuropsychological tests and neuroimaging. Here we report clinically accurate and ultrasensitive detection of multiple AD core biomarkers (t-tau, p-tau(181), A beta(42), and A beta(40)) in human plasma using densely aligned carbon nanotubes (CNTs). The closely packed and unidirectionally aligned CNT sensor array exhibits high precision, sensitivity, and accuracy, evidenced by a low coefficient of variation (93.0%). By measuring the levels of t-tau/A beta(42), p-tau(181)/A beta(42), and A beta(42)/A beta(40) in clinical blood samples, the sensor array successfully discriminates the clinically diagnosed AD patients from healthy controls with an average sensitivity of 90.0%, a selectivity of 90.0%, and an average accuracy of 88.6%.